33 research outputs found
袣谢懈薪懈褔械褋泻懈 蟹薪邪褔懈屑褘械 胁邪褉懈邪薪褌褘 邪薪邪褌芯屑懈懈 胁械褌胁谢械薪懈褟 褔褉械胁薪芯谐芯 褋褌胁芯谢邪 懈 锌褉懈谢械卸邪褖懈褏 泻 薪械屑褍 谢懈屑褎芯褍蟹谢芯胁
Get PDF袥袠袦肖袗孝袠效袝小袣袠袝 校袟袥蝎 /袗袧袗孝袨袦袗袧袚袠袨袚袪袗肖袠携 /袠小袩袗袪孝袝袪袠袨袚袪袗肖袠携 /袠小袩袙袗袟袨袚袪袗肖袠携 /袠小袩袪袝袧孝袚袝袧袨袗袧袚袠袨袚袪袗肖袠携 /袠小袩袦袗袚袧袠孝袧袨袚袨 袪袝袟袨袧袗袧小袗 袠袟袨袘袪袗袞袝袧袠袝 /袠小袩袦袪-孝袨袦袨袚袪袗肖袠携 /袠小袩孝袨袦袨袚袪袗肖袠携, 携袦袪 /袠小袩携袦袪-袠袟袨袘袪袗袞袝袧袠袝 /袠小袩携袦袪-孝袨袦袨袚袪袗肖袠携 /袠小袩袦袗袚袧袠孝袧袨-袪袝袟袨袧袗袧小袧袗携 袗袧袚袠袨袚袪袗肖袠携 /袠小袩袗袧袚袠袨袚袪袗肖袠携 袦袗袚袧袠孝袧袨-袪袝袟袨袧袗袧小袧袗携 /袠小袩袦袪袠-袗袧袚袠袨袚袪袗肖袠携 /袠小袩袗袪孝袝袪袠袠 /袗袧袗孝袨袦袩袝效袝袧袨效袧袗携 袗袪孝袝袪袠携 /袗袧袗孝袨袦小袝袥袝袟袝袧袨效袧袗携 袗袪孝袝袪袠携 /袗袧袗孝袨袦袛袠袗袚袧袨小孝袠袣袗袣袪袨袙袝袧袨小袧蝎袝 小袨小校袛蝎 /袗袧袗孝袨袦 /袗袧袨袦袗袥袗袨袪孝袗 袘袪挟楔袧袗携 /袗袧袗孝袨袦小袝袪袛袝效袧袨-小袨小校袛袠小孝袗携 小袠小孝袝袦袗 /袗袧袗孝袨袦袥袝袙袗携 袞袝袥校袛袨效袧袗携 袗袪孝袝袪袠携袥校效袝袙袗携 袙袠袟校袗袥袠袟袗笑袠携小袠袧袛袪袨袦 袣袨袦袩袪袝小小袠袠 效袪袝袙袧袨袚袨 小孝袙袨袥袗袙袝孝袙袥袝袧袠携 效袪袝袙袧袨袚袨 小孝袙袨袥袗效袪袝袙袧蝎袡 小孝袙袨
Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality
Get PDFBackground and purpose: Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year.
Methods: We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020).
Results: There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths.
Conclusions: During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT
Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.
Get PDFBACKGROUND AND PURPOSE: Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. METHODS: We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). RESULTS: There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. CONCLUSIONS: During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT
Acute Ischemic Stroke Hemorrhagic Transformation at Angiography Before Mechanical Thrombectomy
No full text
Mechanical Thrombectomy in Acute Ischemic Stroke Using a聽Manually Expandable Stent Retriever (Tigertriever)
No full text
Predictors of Successful First-Pass Thrombectomy with a Balloon Guide Catheter: Results of a Decision Tree Analysis
No full text
